Epidemiology of chronic inducible urticaria in Moscow

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


BACKGROUND: Chronic inducible urticaria is a group of diseases that is characterized by the development of wheals, angioedema, or both in response to specific triggers for ≥6 weeks. According to global scientific international literature, the occurrence of chronic inducible urticaria is 0.5% in the general population and approximately 20%−30% in all chronic urticarias. The prevalence of chronic inducible urticaria has no statistical data in the Russian Federation.

AIM: This study aimed to evaluate the region-specific epidemiology of different forms of chronic inducible urticaria.

MATERIALS AND METHODS: The analysis is based on the number of unique cases extracted from the medical care records in the adults’ segment of the digital platform United medical information and analytical system (UMIAS) (outpatient forms) in Moscow from 2017 to 2021, including keyword search.

RESULTS: This study indicated that the prevalence of chronic inducible urticaria in Moscow is correlated with published global epidemiological data. Among patients with chronic inducible urticarial, females predominate (74.2%), and the median age was 43.8 years (37 years in males and 46.4 in females). The most common form in all verified cases of chronic inducible urticaria is symptomatic dermographism (11.12%), followed by contact urticaria (5.36%), cholinergic urticaria (2.28%), cold urticaria (1.92%), delayed pressure urticaria (0.36%), vibratory urticaria (0.11%), aquagenic urticaria (0.1%), and heat urticaria (0.08%). Chronic inducible urticaria rates in Moscow are high, which increase as in global practice. This research has limitations, including the lack of ubiquitous implementation of standard protocols of provocation testing in outpatient units and the low percentage of using validated questionnaires in the routine management of patients with chronic inducible urticaria.

CONCLUSIONS: Further studies dedicated to this topic are greatly necessary to answer a wide spectrum of questions, including the diagnosis process and evaluation of the severity of chronic inducible urticaria, comorbid conditions, and optimization of the treatment protocols adapted for the particular phenotype.

Full Text

Restricted Access

About the authors

Daria S. Fomina

City Clinical Hospital No. 52; First Sechenov Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: daria_fomina@mail.ru
ORCID iD: 0000-0002-5083-6637
SPIN-code: 3023-4538

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, Moscow; Moscow

Natalya P. Maltseva

City Clinical Hospital No. 52

Email: filippova-nataly@mail.ru
ORCID iD: 0000-0002-4022-3570
SPIN-code: 2588-5718


Russian Federation, Moscow

Sofia A. Serdotetskova

City Clinical Hospital No. 52

Email: darklynx813@gmail.com
ORCID iD: 0000-0001-8472-1152
SPIN-code: 6644-6715


Russian Federation, Moscow

Inna V. Danilycheva

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: ivdanilycheva@mail.ru
ORCID iD: 0000-0002-8279-2173
SPIN-code: 4547-3948

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Marina S. Lebedkina

City Clinical Hospital No. 52

Email: marina.ivanova0808@yandex.ru
ORCID iD: 0000-0002-9545-4720
SPIN-code: 1857-8154


Russian Federation, Moscow

Valeriya I. Mikhaylova

City Clinical Hospital No. 52

Email: lera1208@list.ru
ORCID iD: 0000-0003-0921-9212
SPIN-code: 2841-9652


Russian Federation, Moscow

Elena V. Kovalkova

City Clinical Hospital No. 52

Email: kovalkova@ya.ru
ORCID iD: 0000-0002-1212-3767
SPIN-code: 3078-0976


Russian Federation, Moscow

Nikita S. Chikunov

Moscow Center for Innovative Technologies in Healthcare

Email: artlicasio@gmail.com
ORCID iD: 0000-0002-0643-9423


Russian Federation, Moscow

Alexander V. Karaulov

First Sechenov Moscow State Medical University (Sechenov University)

Email: drkaraulov@mail.ru
ORCID iD: 0000-0002-1930-5424
SPIN-code: 4122-5565

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Mariana A. Lysenko

City Clinical Hospital No. 52

Email: gkb52@zdrav.mos.ru
ORCID iD: 0000-0001-6010-7975
SPIN-code: 3887-6250

MD, Dr. Sci. (Med.)

Russian Federation, Moscow


  1. Russian Association of Allergologists and Clinical Immunologists; Russian Society of Dermatovenerologists and Cosmetologists. Federal clinical guidelines. Urticaria. Moscow; 2019. 60 р. (In Russ).
  2. Borzova EY. Diagnosis of chronic induced urticaria. Russ Allergol J. 2019;16(2):5−13. (In Russ).
  3. Zuberbier T, Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766. doi: 10.1111/all.15090
  4. Dice JP. Physical urticaria. Immunol Allergy Clin North Am. 2004;24(2):225–246.vi. doi: 10.1016/j.iac.2004.01.005
  5. Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1119–1130. doi: 10.1016/j.jaip.2018.03.007
  6. Weller K, Altrichter S, Ardelean E, et al. Chronic urticaria. Prevalence, course, prognostic factors and impact. (In German). Hautarzt. 2010;61(9):750–757. doi: 10.1007/s00105-010-1933-8
  7. Siebenhaar F, Weller K, Mlynek A, et al. Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Experimental Dermatol. 2007;32(3):241–245. doi: 10.1111/j.1365-2230.2007.02376.x
  8. Möller A, Henz BM. Cold urticaria. In: Henz BM, Zuberbier T, Grabbe J, Monroe E, eds. Urticaria. Springer; 1998. Р. 69−78.
  9. Katsarou-Katsari A, Makris M, Lagogianni E, et al. Clinical features and natural history of acquired cold urticaria in a tertiary referral hospital: a 10-year prospective study. JEADV. 200822(12):1405–1411. doi: 10.1111/j.1468-3083.2008.02840.x
  10. Zuberbier T, Althaus C, Chantraine-Hess S, Czarnetzki BM. Prevalence of cholinergic urticaria in young adults. J Am Academy Dermatol. 1994;31(6):978–981. doi: 10.1016/s0190-9622(94)70267-5
  11. Chong WS, Khoo SW. Solar urticaria in Singapore: an uncommon photodermatosis seen in a tertiary dermatology center over a 10-year period. Photodermatol Photoimmunol Photomed. 2004;20(2): 101–104. doi: 10.1111/j.1600-0781.2004.00083.x
  12. Kontou-Fili K, Borici-Mazi R, Kapp A, et al. Physical urticaria: classification and diagnostic guidelines. An EAACI position paper. Allergy. 1997;52(5):504–513. doi: 10.1111/j.1398-9995.1997.tb02593.x
  13. Jain SV, Mullins RJ. Cold urticaria: a 20-year follow-up study. JEADV. 2016;30(12):2066–2071. doi: 10.1111/jdv.13841
  14. Kring Tannert L, Stahl Skov P, Bjerremann Jensen L, et al. Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction. Dermatol (Basel, Switzerland). 2012;224(2):101–105. doi: 10.1159/000336572
  15. Curto-Barredo L, Archilla LR, Vives GR, et al. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment. Acta Derm Venereol. 2018;98(7):641–647. doi: 10.2340/00015555-2941
  16. Vadas P, Sinilaite A, Chaim M. Cholinergic urticaria with anaphylaxis: an underrecognized clinical entity. J Allergy Clin Immunol Pract. 2016;4(2):284–291. doi: 10.1016/j.jaip.2015.09.021
  17. Bizjak M, Košnik M, Dinevski D, et al. Risk factors for systemic reactions in typical cold urticaria: results from the COLD-CE study. Allergy. 2022;77(7):2185–2199. doi: 10.1111/all.15194
  18. Trevisonno J, Balram B, Netchiporouk E, Ben-Shoshan M. Physical urticaria: review on classification, triggers and management with special focus on prevalence including a meta-analysis. Postgraduate Med. 2015;127(6):565–570. doi: 10.1080/00325481.2015.1045817
  19. Sánchez J, Amaya E, Acevedo A, et al. Prevalence of inducible urticaria in patients with chronic spontaneous urticaria: associated risk factors. J Allergy Clin Immunol Pract. 2017;5(2):464–470. doi: 10.1016/j.jaip.2016.09.029
  20. Kozel MM, Mekkes J, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Academy Dermatol. 2001;45(3):387–391. doi: 10.1067/mjd.2001.116217
  21. Diehl KL, Erickson C, Calame A, Cohen PR. A woman with solar urticaria and heat urticaria: a unique presentation of an individual with multiple physical urticarias. Cureus. 2021;13(8):e16950. doi: 10.7759/cureus.16950
  22. Cheon HW, Han SJ, Yeo SJ, et al. A case of combined cholinergic and cold urticaria. Korean J Internal Med. 2012;27(4):478–479. doi: 10.3904/kjim.2012.27.4.478
  23. Zimmer S, Peveling-Oberhag A, Weber A, et al. Unique coexistence of cold and solar urticaria and its efficient treatment. Brit J Dermatol. 2016;174(5):1150–1152. doi: 10.1111/bjd.14354
  24. Mathelier-Fusade P, Aissaoui M, Chabane MH, et al. Association of cold urticaria and aquagenic urticaria. Allergy. 1997;52(6):678–679. doi: 10.1111/j.1398-9995.1997.tb01055.x
  25. Church MK, Kolkhir P, Metz M, Maurer M. The role and relevance of mast cells in urticaria. Immunol Rev. 2018;282(1):232–247. doi: 10.1111/imr.12632
  26. Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias ― The EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780–802. doi: 10.1111/all.12884
  27. Pereira A, Motta AA, Kalil J, Agondi RC. Chronic inducible urticaria: confirmation through challenge tests and response to treatment. Einstein (Sao Paulo Brazil). 2020;18:eAO5175. doi: 10.31744/einstein_journal/2020ao5175
  28. Maurer M, Giménez-Arnau A, Ensina LF, et al. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. World Allergy Organization J. 2020;13(9):100460. doi: 10.1016/j.waojou.2020.100460
  29. Koch K, Weller K, Werner A, et al. Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria. J Allergy Clin Immunol. 2016;138(5):1483–1485.e9. doi: 10.1016/j.jaci.2016.05.026
  30. Abajian M, Curto-Barredo L, Krause K, et al. Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria. Acta Derm Venereol. 2016;96(1):56–59. doi: 10.2340/00015555-2150
  31. Rossi O, Piccirillo A, Iemoli E, et al. Socio-economic burden and resource utilisation in Italian patients with chronic urticaria: 2-year data from the AWARE study. World Allergy Organization J. 2020;13(12):100470. doi: 10.1016/j.waojou.2020.100470
  32. Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638–649. doi: 10.1016/j.jaci.2017.06.032
  33. Metz M, Schütz A, Weller K, et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140(3):864–867.e5. doi: 10.1016/j.jaci.2017.01.043
  34. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatological Sci. 2014;73(1):57–62. doi: 10.1016/j.jdermsci.2013.08.011
  35. Maure M, Schütz A, Weller K, et al. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140(3):870–873.e5. doi: 10.1016/j.jaci.2017.01.042
  36. Ghazanfar MN, Sand C, Thomsen SF. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. Brit J Dermatol. 2016;175(2):404–406. doi: 10.1111/bjd.14540

Supplementary files

Supplementary Files
1. Fig. 1. Correlation of the incidence of different chronic inducible urticaria types (in %).

Download (305KB)
2. Fig. 2. Incidence of atopic diseases in patients with chronic inducible urticaria.

Download (249KB)
3. Fig. 3. Incidence of comorbidities in patients with chronic inducible urticaria.Note: GIT: gastrointestinal tract; ENT: otorhinolaryngological (ear, nose, throat) diseases.

Download (256KB)
4. Fig. 4. Increase in the incidence of outpatient visits by patients with cholinergic urticaria, cold urticaria, and dermographic urticaria.

Download (319KB)
5. Fig. 5. Increase in the incidence of outpatient visits by patients with delayed pressure urticaria.

Download (255KB)

Copyright © Pharmarus Print Media, 2022

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies